SAN DIEGO, Nov. 11, 2016
/PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ:
ONCS), a company developing DNA-based intratumoral cancer
immunotherapies, today presented new clinical data from a Phase II
Investigator Sponsored Trial led by the University of California, San Francisco
(UCSF). The data was presented today at an oral poster
presentation (#466) by Dr. Alain
Algazi at the Society for Immunotherapy of Cancer ("SITC")
Annual Meeting in National Harbor, MD.
This single-arm, open-label trial assessed the combination of
OncoSec's investigational intratumoral therapy, ImmunoPulse® IL-12,
and Merck's KEYTRUDA® (pembrolizumab) in patients with unresectable
metastatic melanoma. A predictive biomarker was used to enroll
patients that have a low likelihood of response to an anti-PD1
agent alone, and the purpose of the trial is to assess whether the
addition of ImmunoPulse® IL-12 can increase response rates in these
patients.
The full-text abstract is available and can be viewed on SITC's
website at www.sitcancer.org. The poster presentation and
handout showing the data of the 40% overall response rate (ORR) in
patients predicted not to respond to pembrolizumab are available in
the Publications section of OncoSec's website.
For more information about this trial, please visit:
https://clinicaltrials.gov/ct2/show/NCT02493361?term=pIL-12&rank=3
About the SITC Annual Meeting
The Society for
Immunotherapy of Cancer (SITC) is a non-profit medical
professional society of influential scientists, academicians,
researchers, clinicians, government representatives, and industry
leaders from around the world dedicated to improving cancer patient
outcomes by advancing the science and application of cancer
immunotherapy. Currently, SITC has nearly 1,600 members
representing 17 medical specialties and are engaged in research and
treatment of at least a dozen types of cancer. The 31st SITC
Annual Meeting & Associated Programs will take place
November 11-13, 2016 at the
Gaylord National Hotel & Convention Center in National Harbor,
MD. For more information, please go to
http://www.sitcancer.org/2016.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse®,
for the treatment of cancer. ImmunoPulse® is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse® IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various solid
tumors as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse® IL-12, is currently
in clinical development for several indications, including
metastatic melanoma, head and neck cancer, and triple-negative
breast cancer. The program's current focus is on the significant
unmet medical need in patients with melanoma who are refractory or
non-responsive to anti-PD-1/PD-L1 therapies. In addition to
ImmunoPulse® IL-12, the Company is also identifying and
developing new immune-targeting agents for use with the
ImmunoPulse® platform. For more information, please visit
www.oncosec.com.
University of California
Disclaimer
The information stated above was prepared
by OncoSec Medical Incorporated and reflects solely the opinion of
the corporation. Nothing in this statement shall be construed to
imply any support or endorsement of OncoSec, or any of its
products, by The Regents of the University of
California, its officers, agents and employees.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "will," "can," and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data,
safety and technical issues; our ability to raise additional
funding necessary to fund continued operations; and the other
factors discussed in OncoSec's filings with the Securities and
Exchange Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Contact
Sophia Ononye,
PhD MPH MBA
Associate Director, Investor Relations and Corporate
Communications
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-presents-positive-interim-response-data-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-2016-300361355.html
SOURCE OncoSec Medical Incorporated